ACCESS Newswire

Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans

30.9.2026 15:50:00 CEST | ACCESS Newswire | Press release

Share

NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally.

Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match.

The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata captures 3D data directly, from the bodies themselves-whether those bodies are human or mechanical.

"There's just no substitute for direct 3D motion capture," said Frank Tanner, vice president of robotics and physical AI at Innodata. "When a computer vision model tries to make sense of a 2D grid of pixels, mistakes inevitably creep in. Our sensors are designed to register the tiniest motion of every joint, which makes training more accurate and efficient. When you're training a humanoid that weighs almost 200 pounds, your readings can't be in the ballpark. They need to be precise. And with this lab, they are."

"Plenty of motion capture companies have discovered humanoid robotics lately. But the teams building the most capable robots keep reaching the same conclusion: if the training data is approximate, the robot will be too," said Andrew Knox, managing director of Vicon. "Vicon sets the standard that motion data is measured against. Our systems capture people, robots and the objects they handle in the same space, with sub-millimeter accuracy and millisecond latency. That gives you independent ground truth, not an estimate. It's why the leading humanoid developers, frontier AI labs and research universities keep choosing Vicon, and why Innodata's lab is well placed to become a reference point for the whole physical AI industry."

Innodata customers will be able to purchase motion-capture data as off-the-shelf packages, or commission custom projects. Innodata can produce training data for a wide range of physical AI platforms and retarget motion data from one platform to another as needed.

Customers can also send in robots for evaluation, to confirm they perform to customer specifications. Innodata's lab experts can measure a robot's movements and responses in a variety of scripted scenarios, including those in which robots and people interact. Because the lab's calibrated cameras observe each robot from the outside, they provide an external ("exocentric") check on the robot's internal ("egocentric") telemetry, which is often noisy. The resulting measurements can be used to validate a developer's internal data reports or performance claims or to provide independent, third-party benchmarks for trust and safety.

The motion-capture lab is an important addition to Innodata's physical AI practice, which supports robotics programs across the full data lifecycle. Its work includes end-to-end real-world data capture and training data production spanning humanoids, human-operated hardware, wearable systems, sensor rigs, Universal Manipulator Interface (UMI) grippers, and other multimodal capture set-ups, as well as evaluation and safety-assurance services that validate robot performance. Innodata's physical AI experts apply the same rigorous, multi-stage quality processes the company has honed over decades of delivering premium data for mission-critical use cases in finance, government and healthcare and, more recently, for frontier AI labs.

"Physical AI is growing faster than any other segment in AI, but every robotics team hits the same wall: there isn't enough real-world interaction data, and what exists is expensive and slow to produce," said Innodata CEO Rahul Singhal. "This facility removes that wall. We now offer physical AI companies a complete end-to-end capability - from data collection through model evaluation - that compresses development cycles and gets more capable, safer robots into the world sooner."

To learn more about Innodata's physical AI offerings, contact PhysicalAI@innodata.com.

About Innodata

Innodata (Nasdaq:INOD) is a global data engineering company. We believe that data and Artificial Intelligence (AI) are inextricably linked. Our mission is to enable the responsible advancement of artificial intelligence by providing the data, evaluation frameworks, and human expertise required to build AI systems that can be trusted at scale. We provide a range of transferable solutions, platforms, and services for Generative AI / AI builders and adopters. In every relationship, we honor our 36+ year legacy delivering the highest quality data and outstanding outcomes for our customers.

Visit www.innodata.com to learn more.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements include, without limitation, statements concerning our operations, economic performance, financial condition, developmental program expansion, and position in the AI services market. Words such as "project," "forecast," "believe," "expect," "can," "continue," "could," "intend," "may," "should," "will," "anticipate," "indicate," "guide," "predict," "likely," "estimate," "plan," "potential," "possible," "promises," or the negatives thereof, and other similar expressions generally identify forward-looking statements.

These forward-looking statements are based on management's current expectations, assumptions and estimates and are subject to a number of risks and uncertainties, including, without limitation, impacts resulting from ongoing geopolitical conflicts; anticipated and actual use cases and outcomes; investments in large language models; that contracts may be terminated by customers; projected or committed volumes of work may not materialize; pipeline opportunities and customer discussions which may not materialize into work or expected volumes of work; the likelihood of continued development of the AI markets, particularly new and emerging markets, that our services support; the ability and willingness of our customers and prospective customers to execute business plans that give rise to requirements for our services; continuing reliance on project-based work and the primarily at-will nature of such contracts and the ability of these customers to reduce, delay or cancel projects; potential inability to replace projects that are completed, canceled or reduced; revenue concentration among a limited number of customers; our dependency on third-party providers and partners; our ability to achieve revenue and growth targets; difficulty in integrating and deriving synergies from acquisitions, joint ventures and strategic investments; potential undiscovered liabilities of companies and businesses that we may acquire; potential impairment of the carrying value of goodwill and other acquired intangible assets of companies and businesses that we acquire; a continued downturn in or depressed market conditions; changes in external market factors; the potential effects of U.S. global trade and monetary policy, including the interest rate policies of the Federal Reserve; changes in our business or growth strategy; the emergence of new, or growth in existing competitors; various other competitive and technological factors; our use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or company information, or service interruptions; and other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission ("SEC").

Our actual results could differ materially from the results referred to in any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks discussed in Part I, Item 1A. "Risk Factors," Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations," and other parts of our Annual Report on Form 10-K, filed with the SEC on February 26, 2026, and in the other filings that we may make with the SEC. In light of these risks and uncertainties, there can be no assurance that the results referred to in any forward-looking statements will occur, and you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof.

We undertake no obligation to update or review any guidance or other forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by the U.S. federal securities laws.

Company Contact

Aneesh Pendharkar
investor@innodata.com
(201) 371-8000

Media Contact

Maura Lafferty
Firebrand Communications for Innodata
innodata@firebrand.marketing
(415) 848-9175

SOURCE: Innodata Inc.

Innodata Inc.

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release

PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path

Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in

Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release

LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als

Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release

NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr

Gedeon Richter Launches Online Platform for Transdiagnostic Global Impression Scales and New Caregiver Book at Next Step Conference29.9.2026 14:00:00 CEST | Press release

BUDAPEST, HU / ACCESS Newswire / September 29, 2026 / Gedeon Richter welcomed 145 participants from 27 countries to the latest edition of Next Step, the company's international conference for psychiatrists, held in September at the Hungarian Academy of Sciences. "At Gedeon Richter, we see partnerships as a cornerstone of advancing psychiatric care. By supporting healthcare professionals, patients, and caregivers alike, we can help create meaningful improvements in outcomes, functioning, and quality of life for people living with mental health conditions," said Kristóf Kóczián, Head of Global Business Development and CNS Business Unit at Gedeon Richter in his opening speech. The scientific programme explored how psychiatric care can move beyond diagnostic labels and adopt a more personalized, measurement-based approach. The presentations highlighted how personalized, measurement-based care can be integrated into everyday clinical practice, with a focus on cognitive symptoms, treatment-r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye